Market capitalization | JPY154.94b |
Enterprise Value | JPY553.83b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.76 |
P/S ratio (TTM) P/S ratio | 0.49 |
P/B ratio (TTM) P/B ratio | 0.99 |
Dividend yield | 5.38% |
Last dividend (FY23) | JPY21.00 |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
7 Analysts have issued a Sumitomo Dainippon Pharma forecast:
7 Analysts have issued a Sumitomo Dainippon Pharma forecast:
Mar '24 |
+/-
%
|
||
Turnover | 314,558 314,558 |
43%
43%
|
|
Gross income | 187,981 187,981 |
50%
50%
|
|
EBITDA | -134,010 -134,010 |
129%
129%
|
EBIT (operating result) EBIT | -171,775 -171,775 |
72%
72%
|
Net profit | -314,969 -314,969 |
323%
323%
|
Figures in millions JPY.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.
Head office | Japan |
CEO | Toru Kimura |
Employees | 4,980 |
Founded | 1897 |
Website | www.sumitomo-pharma.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.